Abstract 1212P
Background
Severe irAEs caused by ICIs affect treatment efficacy and benefit. Current research on irAEs is mainly focused on early prediction, with a lack of near-term prediction. Studies have reported that baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and absolute eosinophil count (AEC) can predict irAEs. Our aim is to explore the near-term predictive value of NLR, PLR, and AEC for grade 3 or higher irAEs caused by PD-1 inhibitors.
Methods
Data were collected from cancer patients treated with PD-1 inhibitors in our department from January 2020 to May 2022. NLR, PLR, and AEC data were collected one cycle before and during the occurrence of irAEs (median cycle number was 2nd and 3rd cycles, respectively). Logistic analysis was used to analyze the correlation between NLR, PLR, AEC, and irAEs, and to construct a prediction model. The model's performance was assessed by obtaining sensitivity and specificity through the ROC.
Results
Out of the 138 cancer patients, 47 experienced grade 1-2 irAEs, and 18 had grade 3 or higher irAEs (including 2 fatal irAEs). Multivariate analysis showed that the current cycle's NLR (OR, 1.839, p=0.000) and PLR (OR, 0.994, p=0.029) were independent risk factors for irAEs. Model A predicted the occurrence of irAEs in the next cycle with an area under the curve (AUC) of 0.788, a sensitivity of 69.2%, and a specificity of 68.5%. When the Model A was ≥38.8% (cutoff value), Model B (AUC =0.900) was entered, predicting the occurrence of grade 3 or higher irAEs in the next cycle with a sensitivity of 67.7% and a specificity of 72.6%. Similarly, Model C predicted the occurrence of irAEs in the current cycle (AUC=0.865) yielded a sensitivity of 81.5% and a specificity of 86.3%. When the Model C was ≥52.8%, Model D was entered, predicting the occurrence of grade 3 or higher irAEs in the current cycle (AUC=0.888) with a sensitivity of 83.3% and a specificity of 83.0%.
Conclusions
The model consisting of NLR, PLR, and AEC in this study can predict the occurrence of grade 3 or higher irAEs within one cycle. Compared with early prediction, our near-term prediction model maximizes the number of cycles of immune therapy obtained by patients, thereby improving the effectiveness of immunotherapy, which has significant clinical value.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14